Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
In This Article:
Pfizer PFE announced that it has selected its preferred once-daily modified-release formulation of danuglipron, its oral GLP-1 receptor agonist, for further development as a weight loss pill based on encouraging results from an ongoing study. It evaluated several formulations of danuglipron and said that one showed “the most favorable profile.” Pfizer, however, did not announce any detailed clinical data from the study.
In the second half of the year, Pfizer will conduct dose optimization studies on multiple doses of the preferred modified-release formulation to select the optimal dose to move forward to pivotal studies.
Previously, Pfizer faced setbacks related to its pipeline candidates for obesity. In December last year, Pfizer announced that it would not move forward with phase III studies on the twice-daily formulation of danuglipron. Though the candidate was effective in reducing weight in a phase IIb study, it caused several gastrointestinal side effects like nausea, vomiting and diarrhea. Back then, the company said that the pharmacokinetic study of the once-daily formulation of danuglipron continues and it will focus on its development. In June 2023, Pfizer dropped the development of another GLP-1-RA candidate, lotiglipron, due to elevated levels of a type of liver enzymes seen in a study.
Along with the latest release, Pfizer said that data from studies on the once-daily formulations have shown a similar safety profile to the twice-daily formulation. However, treatment with danuglipron did not lead to any increased incidence of liver enzyme elevation in more than 1,400 study participants.
Pfizer said it has three clinical and several pre-clinical candidates in its pipeline for obesity, with danuglipron being the most advanced.
Pfizer’s shares were up slightly more than 1% as its announcement to move forward with the development of the once-daily weight loss pill marks its comeback to the obesity space.
Year to date, the stock has declined 0.5% against the industry’s 23.3% rise.
Image Source: Zacks Investment Research
Obesity has become a global health problem as it can cause other diseases like heart disease, diabetes and stroke, leading to an exponential increase in demand for obesity medicines. Also, social media has somewhat hyped the benefits of these medications.
The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks.